BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $1.13, $0.43 better than the analyst estimate of $0.70. Revenue for the quarter came in at $745 million versus the consensus estimate of $741.02 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.